During the past decade, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 10 clinical trials were completed, i.e. on average, 90.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 8 clinical trials were completed. i.e. 800% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" #1 sponsor was "Pfizer" with 4 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Ferring Pharmaceuticals" with 1 trials sponsored and "Galapagos NV" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Korean Cancer Study Group" with 1 trials as a collaborator and "Tokyo Medical and Dental University" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" are "Rheumatoid Arthritis" (3 trials), "Nonalcoholic Steatohepatitis" (2 trials), "Amyloidosis" (1 trials), "Chronic Pain" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" in a lesser frequency.

Most popular intervention types in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" are "Drug" (14 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Bortezomib" (2 trials), "Placebo to match SEL 18 mg" (2 trials), "Placebo to match SEL 6 mg" (2 trials) and "SEL" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".